603222.SHG Zhejiang Chimin Pharm Co Ltd
- Market cap
- CNY 3.73B
- P/E
- -
- P/B
- 3.36x
- ROE
- -10.4%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603222.SHG undervalued?
Graham numberThe Graham number of Zhejiang Chimin Pharm Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Chimin Pharm Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Chimin Pharm Co Ltd yet.
Zhejiang Chimin Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells in vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-pipe double-valve, single-pipe single-valve, and single-pipe double-valve soft bags; plastic bottles; and other packaging forms. It also offers injection puncture medical devices, including safety syringes, safety injection needles, sterile syr…
Full company profileZhejiang Chimin Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Chimin Pharm Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 450M | 603M | 698M | 771M | 878M | 1.10B | 837M | 895M | 776M | 686M | 664M |
| Gross Profit | 205M | 271M | 288M | 351M | 357M | 526M | 386M | 379M | 280M | 213M | 213M |
| Operating Income | 47.1M | 74.1M | 55.1M | 90.7M | 31.5M | 168M | 46.0M | -43.8M | -63.6M | -94.3M | -71.9M |
| EBITDA | 79.4M | 121M | 124M | 192M | 117M | 292M | 145M | 64.9M | 54.3M | -99.5M | -93.0M |
| Net Income | 40.9M | 52.9M | 32.1M | 69.2M | 6.40M | 148M | 34.5M | -65.5M | -59.7M | -246M | -110M |
| EPS | 0.09 | 0.12 | 0.07 | 0.16 | 0.01 | 0.31 | 0.07 | -0.12 | -0.11 | -0.47 | -0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 922M | 1.57B | 2.12B | 2.08B | 2.29B | 2.43B | 2.71B | 2.48B | 2.41B | 2.31B | 2.16B |
| Total Liabilities | 113M | 647M | 1.08B | 1.01B | 1.25B | 1.05B | 940M | 820M | 846M | 1.00B | 1.03B |
| Shareholders' Equity | 751M | 793M | 810M | 872M | 865M | 1.24B | 1.71B | 1.58B | 1.48B | 1.22B | 1.05B |
| Cash & Short-term Investments | 241M | 180M | 269M | 284M | 372M | 356M | 649M | 361M | 313M | 295M | 231M |
| Total Debt | 2.20M | 340M | 715M | 726M | 796M | 650M | 597M | 460M | 503M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 72.1M | 66.5M | 124M | 153M | 166M | 289M | 205M | 140M | 73.0M | -10.4M | - |
| Capital Expenditure | 97.6M | 335M | 261M | 134M | 168M | 297M | 196M | 149M | 122M | 46.2M | 53.4M |
| Free Cash Flow | -25.5M | -268M | -137M | 18.6M | -1.46M | -7.25M | 8.54M | -9.02M | -49.0M | -56.6M | -27.4M |
| Ratios | |||||||||||
| ROE | 5.4% | 6.7% | 4.0% | 7.9% | 0.7% | 11.9% | 2.0% | -4.2% | -4.0% | -20.1% | -10.4% |
| ROA | 4.4% | 3.4% | 1.5% | 3.3% | 0.3% | 6.1% | 1.3% | -2.6% | -2.5% | -10.6% | -5.1% |
| Net Profit Margin | 9.1% | 8.8% | 4.6% | 9.0% | 0.7% | 13.4% | 4.1% | -7.3% | -7.7% | -35.8% | -16.5% |
| Debt to Equity | 0.00x | 0.43x | 0.88x | 0.83x | 0.92x | 0.52x | 0.35x | 0.29x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Chimin Pharm Co Ltd dividends
- Dividend yield
- 0.53%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 7, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 19.8M | 0.04 | - |
| 2024 | CNY 16.7M | 0.03 | - |
| 2023 | CNY 10.7M | 0.02 | - |
| 2022 | CNY 30.7M | 0.06 | 89.0% |
| 2021 | CNY 38.0M | 0.08 | 25.7% |
| 2020 | CNY 15.4M | 0.03 | 240.1% |
| 2019 | CNY 6.72M | 0.02 | 9.7% |
| 2018 | CNY 44.0M | 0.10 | 137.1% |
| 2017 | CNY 24.9M | 0.06 | 47.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 20, 2022.
Who owns Zhejiang Chimin Pharm Co Ltd
- Insiders 42.34%
- Institutions 0.76%
- Public & others 56.90%
- Shares outstanding 525M
- Free float 312M
Zhejiang Chimin Pharm Co Ltd company profile
- Company name
- Zhejiang Chimin Pharm Co Ltd
- Ticker
- 603222.SHG
- ISIN
- CNE100002193
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,890
- Fiscal year end
- December
- Address
- No. 888, Beiyuan Road, Taizhou, China, 318020
- Phone
- 86 57 6840 66588
- Website
- chimin.cn
About Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells in vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-pipe double-valve, single-pipe single-valve, and single-pipe double-valve soft bags; plastic bottles; and other packaging forms. It also offers injection puncture medical devices, including safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, infusion sets, precision filter infusion sets, and other products. In addition, the company provides in vitro diagnostics products, such as clinical chemical diagnostic, immunological diagnostic, blood testing, rapid diagnostic, and enzyme-linked immunological diagnostic reagents; laboratory instruments; and in vitro diagnostic medical products, as well as FOB fecal occult blood automated immunoassay monitoring and pylori Helicobacter detection kits. Further, it offers hemodialysis series products, including hemodialysis concentrate, and other products; and medical and health services. The company was formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd. and changed its name to Chimin Health Management Co., Ltd. in August 2018. Chimin Health Management Co., Ltd. was founded in 1996 and is based in Taizhou, China.
Zhejiang Chimin Pharm Co Ltd management
7- Mr. Yunfei TianPresident & Director · born 1982
- Mr. Yang GuoweiFinancial Director · born 1983
- Mr. Gao Peng QiuExecutive VP & Director · born 1974
- Mr. Fudan ShangguanEmployee Representative Director & Production Director · born 1979
- Mr. Kun ChenDirector, VP & Board Secretary · born 1983
- Mr. Yong BieVice President · born 1976
- Hewei WangAccounting Supervisor